GeoVax Labs, Inc.
No enriched coverage for $GOVX in the last 7 days.
No SEC Form 4 filings for $GOVX in the last 30 days.
See all $GOVX insider activity →GeoVax Labs (GOVX) highlighted CDC reports of sustained Clade Ib mpox transmission in the U.S. The company is advancing its GEO-MVA vaccine, aiming to start a Phase 3 trial in Q4 2026 with results expected in mid-2027. GeoVax believes its vaccine could diversify supply and enhance preparedness.
GeoVax Labs, Inc. (GOVX) announced the development of a vaccine construct targeting Bundibugyo virus (BDBV) using its proprietary MVA-based rapid-cloning technology. The construct is a milestone toward a potential BDBV vaccine candidate, building on the company's existing filovirus vaccine portfolio. GeoVax's GEO-MVA vaccine for mpox and smallpox remains its primary focus, with a Phase 3 trial planned for late 2026. The World Health Organization (WHO) has called for accelerated development of BD
GeoVax Labs (GOVX) supports a new global mpox vaccine stockpile initiative, funded by Gavi and WHO. The stockpile aims to provide equitable access to vaccines during outbreaks. GeoVax's CEO highlights the need for durable procurement and sufficient supply. The company's GEO-MVA vaccine candidate is advancing toward a Phase 3 study in 2026, with key milestones already achieved. GeoVax seeks to contribute to global supply resilience.
Recent GOVX coverage spans technology, corporate actions and financial news.
The announcement may lift sentiment on GeoVax as investors anticipate a near‑term data readout, but the modest scale of the trial and limited market exposure temper upside.
The construct is an early-stage development milestone; no immediate commercial impact but may boost R&D pipeline perception.
The stockpile initiative could boost demand for GeoVax's MVA‑based vaccine, supporting near‑term revenue visibility.
The capital raise provides modest near‑term funding, likely offering slight price support.
The cash infusion modestly improves short‑term liquidity but is unlikely to move the stock significantly.
AlphAI scores every news story that mentions GOVX with an AI model for sentiment and relevance, and aggregates insider trades from GeoVax Labs, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
GeoVax Labs (GOVX) highlighted CDC reports of sustained Clade Ib mpox transmission in the U.S. The company is advancing its GEO-MVA vaccine, aiming to start a Phase 3 trial in Q4 2026 with results expected in mid-2027. GeoVax believes its vaccine could diversify supply and enhance preparedness.
3 min readGeoVax Labs, Inc. (GOVX) announced the development of a vaccine construct targeting Bundibugyo virus (BDBV) using its proprietary MVA-based rapid-cloning technology. The construct is a milestone toward a potential BDBV vaccine candidate, building on the company's existing filovirus vaccine portfolio. GeoVax's GEO-MVA vaccine for mpox and smallpox remains its primary focus, with a Phase 3 trial planned for late 2026. The World Health Organization (WHO) has called for accelerated development of BD
2 min readGeoVax Labs (GOVX) supports a new global mpox vaccine stockpile initiative, funded by Gavi and WHO. The stockpile aims to provide equitable access to vaccines during outbreaks. GeoVax's CEO highlights the need for durable procurement and sufficient supply. The company's GEO-MVA vaccine candidate is advancing toward a Phase 3 study in 2026, with key milestones already achieved. GeoVax seeks to contribute to global supply resilience.
2 min readGeoVax Labs, Inc. (GOVX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 GeoVax Announces a Warrant Inducement Transaction ATLANTA, GA – August 26, 2026 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its entry into a warrant inducement agreement with an e
2 min readGeoVax Labs (GOVX) announced a warrant inducement transaction with an institutional investor. The investor will exercise existing warrants to purchase up to 5.7 million shares at $0.64 per share, generating approximately $3.65 million in proceeds. In return, the investor will receive new warrants for up to 11.4 million shares. The company plans to use the net proceeds for working capital and general corporate purposes. The transaction is expected to close on August 27, 2026, subject to customary
1 min readGeoVax Labs (GOVX) selected a CRO and European clinical sites for its Phase 3 study of GEO-MVA, a vaccine against mpox and smallpox. The study, planned for Q4 2026, will enroll 500 healthy adults and compare GEO-MVA's immunogenicity and safety to a licensed MVA vaccine. GeoVax aims to announce results by mid-2027, with the study's success potentially supporting EMA approval.
2 min readWerewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.
2 min readGeoVax (Nasdaq: GOVX) said it is highlighting its MVA-based hemorrhagic fever vaccine expertise amid a rapidly expanding Ebola outbreak in the DRC caused by Bundibugyo virus. The WHO reports 4,300+ cases and 2,000 deaths, with no approved BDBV vaccine. GeoVax plans to start a pivotal GEO-MVA immunobridging program in 2H 2026.
3 min readGeoVax Labs (Nasdaq: GOVX) said the FDA accelerated approval of TUDRIQEV (formerly RP1) plus nivolumab for unresectable advanced cutaneous melanoma after prior anti-PD-1 therapy supports momentum for intratumoral, tumor-directed immunotherapies. GeoVax highlighted its investigational Gedeptin tumor-priming approach and cited JCI Insight preclinical data showing enhanced immune responses with anti-PD-1. The company plans a next-phase study with pembrolizumab in head and neck cancer.
5 min readGeoVax Labs (NASDAQ:GOVX) says it plans to start a pivotal Phase 3 trial of its GEO-MVA mpox and smallpox vaccine before end-2024. The EMA granted an expedited pathway, waiving Phase 1 and 2, requiring an immunobridging study versus Bavarian Nordic’s MVA-BN. GeoVax cites a ~15 million dose annual MVA supply gap and targets government stockpiles.
3 min read
